The Society for Women’s Health Research (SWHR) this month announced that it will be overseeing the administration of the Coalition to Advance Maternal Therapeutics (CAMT), a coalition founded in 2014 to advocate for policy changes and raise awareness of the need for greater inclusion of pregnant and lactating populations in clinical research.
Recognizing that not enough is known about the effect of most drugs on a woman and her pregnancy, the goal of the CAMT is to create better understanding of the safety and efficacy of prescription drugs, therapeutics, and vaccines used during pregnancy and breastfeeding. Throughout the year, the CAMT and its member organizations are committed to raising awareness among policymakers and industry about the need to include pregnant and lactating women in clinical trials, where appropriate, to close gaps in knowledge and improve the health of women and their families.
SWHR, as an initial member of the CAMT and one of the four permanent members of the coalition’s Steering Committee, is well-suited to take on the administration responsibilities of the CAMT, which will include ensuring funding, administrative, and logistics support in coordination with the other Steering Committee members. The Society for Maternal-Fetal Medicine will continue to serve in the role of Chair of the CAMT.
This change in administration—along with a new, formalized membership structure—will equip the CAMT to identify and address areas of need and quickly respond to evolving policy opportunities.
For more information about CAMT, please visit safemeds4moms.org or contact SWHR Chief Advocacy Officer Lindsey Horan or CAMT Steering Committee Chair Rebecca Abbott. For questions about membership, please contact the Development Team.